Suzhou‑based Alphamab reported Phase 3 KC‑Wise results showing its HER2 bispecific antibody anbenitamab (KN‑026) plus chemotherapy reduced progression risk by 75% in patients with HER2‑positive gastric or gastroesophageal junction cancer who had failed prior trastuzumab‑containing therapy. The randomized, double‑blind, controlled multicenter trial—published in Annals of Oncology—met its primary endpoint and positions the bispecific as a potential new standard in second‑line HER2‑positive gastric cancer.